Alvotech’s AVT05, a proposed biosimilar candidate to Simponi and Simponi Aria (golimumab), has entered its first pharmacokinetic study.
In addition to pharmacokinetics, the study will assess the comparative safety and tolerability of AVT05 in healthy adult subjects
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?